-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The downstream of pharmaceutical equipment is mainly the pharmaceutical industry, including chemical raw materials industry, chemical drug preparation industry, traditional Chinese medicine decoction pieces and biopharmaceutical industry
.
Its market development is closely linked to the needs of the pharmaceutical industry
.
So, in 2022, how will the needs of the downstream sub-industries of pharmaceutical equipment change, and what opportunities will the pharmaceutical equipment industry face? This article briefly discusses the needs of each sub-industry of the pharmaceutical industry, and discusses the opportunities and prospects of the pharmaceutical equipment industry in the new year
.
Pharmaceutical Equipment (Source: Pharmaceutical Network) API Industry: Opportunities and challenges coexist, and the process needs to be innovated urgently.
China is a major producer and exporter of APIs.
Among them, the export scale of APIs is close to about 20% of the global API market share
.
According to the statistics of China Pharmaceutical Enterprise Management Association, in 2020, China's chemical raw materials industry will achieve operating income of nearly 400 billion yuan, an increase of 4.
4% compared with the previous year
.
As the focus of global chemical pharmaceuticals gradually shifts to developing countries, China's API industry is expected to undertake more opportunities
.
But at the same time, policies and measures such as the "Implementation Plan for Promoting the High-Quality Development of the API Industry" are also supporting the industry's development in an innovation-driven, green and low-carbon high-quality direction, and encouraging the cultivation of new advantages in international competition
.
In this context, the production process of APIs is in urgent need of innovation and upgrading, which will also bring opportunities and challenges to the API equipment industry
.
Formulation industry: rapid development, strong demand for special equipment From the perspective of the development status of the formulation industry, with the strong support of the national industrial policy and the expansion of market demand, China's chemical preparation manufacturing industry has developed rapidly
.
Data show that in 2020, the main business income of China's chemical preparation industry will be 835.
7 billion yuan
.
According to the different progress of innovation, chemical preparations can be divided into innovative drugs and generic drugs
.
In the past, generic drugs occupied the main drug market share in China.
In recent years, pharmaceutical innovation has become a trend, and high-end generic drugs and innovative drugs have become the direction of research and development
.
However, due to the high cost and high risk of innovative drug R&D, its "close relatives" two types of improved new drugs have ushered in a R&D climax due to their prominent advantages.
.
The data shows that in the nearly 3 years from 2019 to 2021, the registration acceptance of chemical drug class 2 improved new drugs showed an overall upward trend
.
The total number of IND applications has increased from 188 in 2019 to 418 in 2021, with an annual growth rate of nearly 49%; among them, the number of IND applications has increased from 141 in 2019 to 304 in 2021, with an annual growth rate of nearly 47%.
%
.
It is foreseeable that with the continuous advancement of the research and development of innovative drugs and improved new drugs, the development of the entire formulation industry is expected to further accelerate
.
In the production process of preparations, a lot of special equipment is often involved, as well as environmental protection equipment that adapts to the new standard operation of the industry.
In the past, pharmaceutical factories mainly relied on expensive imported equipment.
.
Chinese medicine decoction pieces industry: Chinese medicine granules have great potential, and the processing equipment industry has the potential to be tapped.
Due to the strong support at the national and local levels, the Chinese medicine business continues to grow and develop, which has also driven the growth of the market demand for Chinese medicine decoction pieces in China.
With the tightening of industry regulation, the overall growth rate of the industry has slowed down
.
Relevant statistics show that in 2020, the main business income of China's traditional Chinese medicine decoction pieces processing industry is about 160 billion yuan, a decrease of more than 30 billion yuan from 193.
25 billion yuan in 2019
.
However, it should be noted that Chinese herbal formula granules are expected to gradually replace the market share of decoction pieces and proprietary Chinese medicines in medical institutions, with huge potential.
Especially after the pilot work is over, the entire market will develop in a healthy and standardized direction, aiming at the 100 billion market.
.
The "Announcement on Ending the Pilot Work of TCM Formula Granules" clarifies that enterprises should have complete production capacity for TCM processing, extraction, separation, concentration, drying, and granulation
.
In this context, the processing equipment industry upstream of traditional Chinese medicine formula granules will also be excavated
.
Biopharmaceutical industry: rapid development, the space for upstream equipment replacement will be opened In recent years, under the resonance of policies, talents, capital and other factors, China's biopharmaceutical industry has developed rapidly, and the demand for high-end pharmaceutical equipment has continued to expand
.
In 2020, the main business income of the biopharmaceutical industry is about 277.
7 billion yuan
.
The industry predicts that by 2025, only the biopharmaceutical market in China's biopharmaceutical field will exceed the 800 billion mark
.
The industry pointed out that with the rising labor costs, biopharmaceutical companies generally face the challenge of cost control.
Domestic biopharmaceutical equipment companies with strong R&D strength and rich experience are expected to win room for growth and accelerate the pace of import substitution
.
.
Its market development is closely linked to the needs of the pharmaceutical industry
.
So, in 2022, how will the needs of the downstream sub-industries of pharmaceutical equipment change, and what opportunities will the pharmaceutical equipment industry face? This article briefly discusses the needs of each sub-industry of the pharmaceutical industry, and discusses the opportunities and prospects of the pharmaceutical equipment industry in the new year
.
Pharmaceutical Equipment (Source: Pharmaceutical Network) API Industry: Opportunities and challenges coexist, and the process needs to be innovated urgently.
China is a major producer and exporter of APIs.
Among them, the export scale of APIs is close to about 20% of the global API market share
.
According to the statistics of China Pharmaceutical Enterprise Management Association, in 2020, China's chemical raw materials industry will achieve operating income of nearly 400 billion yuan, an increase of 4.
4% compared with the previous year
.
As the focus of global chemical pharmaceuticals gradually shifts to developing countries, China's API industry is expected to undertake more opportunities
.
But at the same time, policies and measures such as the "Implementation Plan for Promoting the High-Quality Development of the API Industry" are also supporting the industry's development in an innovation-driven, green and low-carbon high-quality direction, and encouraging the cultivation of new advantages in international competition
.
In this context, the production process of APIs is in urgent need of innovation and upgrading, which will also bring opportunities and challenges to the API equipment industry
.
Formulation industry: rapid development, strong demand for special equipment From the perspective of the development status of the formulation industry, with the strong support of the national industrial policy and the expansion of market demand, China's chemical preparation manufacturing industry has developed rapidly
.
Data show that in 2020, the main business income of China's chemical preparation industry will be 835.
7 billion yuan
.
According to the different progress of innovation, chemical preparations can be divided into innovative drugs and generic drugs
.
In the past, generic drugs occupied the main drug market share in China.
In recent years, pharmaceutical innovation has become a trend, and high-end generic drugs and innovative drugs have become the direction of research and development
.
However, due to the high cost and high risk of innovative drug R&D, its "close relatives" two types of improved new drugs have ushered in a R&D climax due to their prominent advantages.
.
The data shows that in the nearly 3 years from 2019 to 2021, the registration acceptance of chemical drug class 2 improved new drugs showed an overall upward trend
.
The total number of IND applications has increased from 188 in 2019 to 418 in 2021, with an annual growth rate of nearly 49%; among them, the number of IND applications has increased from 141 in 2019 to 304 in 2021, with an annual growth rate of nearly 47%.
%
.
It is foreseeable that with the continuous advancement of the research and development of innovative drugs and improved new drugs, the development of the entire formulation industry is expected to further accelerate
.
In the production process of preparations, a lot of special equipment is often involved, as well as environmental protection equipment that adapts to the new standard operation of the industry.
In the past, pharmaceutical factories mainly relied on expensive imported equipment.
.
Chinese medicine decoction pieces industry: Chinese medicine granules have great potential, and the processing equipment industry has the potential to be tapped.
Due to the strong support at the national and local levels, the Chinese medicine business continues to grow and develop, which has also driven the growth of the market demand for Chinese medicine decoction pieces in China.
With the tightening of industry regulation, the overall growth rate of the industry has slowed down
.
Relevant statistics show that in 2020, the main business income of China's traditional Chinese medicine decoction pieces processing industry is about 160 billion yuan, a decrease of more than 30 billion yuan from 193.
25 billion yuan in 2019
.
However, it should be noted that Chinese herbal formula granules are expected to gradually replace the market share of decoction pieces and proprietary Chinese medicines in medical institutions, with huge potential.
Especially after the pilot work is over, the entire market will develop in a healthy and standardized direction, aiming at the 100 billion market.
.
The "Announcement on Ending the Pilot Work of TCM Formula Granules" clarifies that enterprises should have complete production capacity for TCM processing, extraction, separation, concentration, drying, and granulation
.
In this context, the processing equipment industry upstream of traditional Chinese medicine formula granules will also be excavated
.
Biopharmaceutical industry: rapid development, the space for upstream equipment replacement will be opened In recent years, under the resonance of policies, talents, capital and other factors, China's biopharmaceutical industry has developed rapidly, and the demand for high-end pharmaceutical equipment has continued to expand
.
In 2020, the main business income of the biopharmaceutical industry is about 277.
7 billion yuan
.
The industry predicts that by 2025, only the biopharmaceutical market in China's biopharmaceutical field will exceed the 800 billion mark
.
The industry pointed out that with the rising labor costs, biopharmaceutical companies generally face the challenge of cost control.
Domestic biopharmaceutical equipment companies with strong R&D strength and rich experience are expected to win room for growth and accelerate the pace of import substitution
.
